Programme

Pre-Conference Course

OSTEOPOROSIS: ESSENTIALS OF DENSITOMETRY, DIAGNOSIS AND MANAGEMENT COURSE
Wed, November 28
13.30 - 17.10
13.30
Welcome and Opening Remarks — N. Pocock and A. Mithal
13.40
Overview of Osteoporosis — N. Pocock
14.30
Bone Measurement Device Operating Principles — S. Baldwin
15.20
Coffee Break
15.40
X-Ray Science, Radiation Safety and Quality Assurance — N. Pocock
16.20
Clinical Evaluation of Bone Health — D. Chan
Thu, November 29
08.00 - 17.00
08.00
Use of Bone Densitometry for the Diagnosis of Osteoporosis — J. Center
08.50
Fracture Risk Assessment — S. Baldwin
09.40
Monitoring Treatment of Osteoporosis — J. Wark
10.30
Coffee Break
10.50
Clinical Management Part 1: Non-Pharmacologic, Estrogen & SERM Treatment — S. Ferrari
11.40
Clinical Management Part 2: Pharmacological Treatment Continued — J. Center
12.30
Lunch Break
13.30
Clinical Management Part 3: Further Pharmacologic Treatment Considerations — M. Chandran
14.20
Principles of DXA Scan Interpretation — N. Pocock
15.10
Coffee Break
15.30
Principles of Reporting DXA Scans — N. Pocock
16.20
Cases for Discussion — N. Pocock

Conference

Thu, November 29
17.30
OPENING CEREMONY
  • Welcome — C. Cooper, J. A. Kanis & M. Chandran
  • Best clinical papers of 2018 — R. Rizzoli
  • Inclusion of diversity in science — S. Brennan Olsen
  • Hearing the Consumer voice — G. Lyubomirsky
  • Osteoporosis, global challenge, local impacts — L. March
  • Conclusion
19.30
20.30
Welcome Cocktail
Fri, November 30
08.00
19.00
EXHIBITION AREA OPEN
08.15
PLENARY SESSION I
Improving the identification of high risk patients
Chair: J. A. Kanis & E. Seeman
  • Can FRAX be improved — J. A. Kanis
  • CTF/FLS: what have we achieved — C. Cooper
  • New imaging modalities — S. Ferrari
09.30
ORAL COMMUNICATIONS SESSION I
Chair: J. Eisman
  • 9.30 — OC1 — T-SCORE AS AN INDICATOR OF FRACTURE RISK ON THERAPY: EVIDENCE FROM ROMOSOZUMAB VS ALENDRONATE TREATMENT IN THE ARCH TRIAL — C. Tolman
  • 9.40 — OC2 — DENOSUMAB COMPARED WITH RISEDRONATE IN GLUCOCORTICOID-TREATED SUBJECTS: RESULTS FROM THE FINAL 24-MONTH ANALYSIS OF A RANDOMIZED, DOUBLE-BLIND, DOUBLE-DUMMY STUDY — C. Tolman
  • 9.50 — OC3 — VITAMIN D SUPPLEMENTATION IN PREGNANCY: A RANDOMIZED DOUBLE-BLIND CONTROLLED TRIAL — R. Khadgawat
10.00
INDUSTRY-SPONSORED SATELLITE SYMPOSIUM (Detailed programme here)
11.00
PLENARY SESSION II
Similarities and differences in fracture risk and treatments respone: Asia vs West (IOF-OA session)
Chair: C. Cooper (IOF) & G. Lyubomirsky (OA)
  • BMD and other parameters of bone in Asia vs West — K. Sanders
  • FRAX: intervention threshold in Asia vs West — E. Lau
  • Response to osteoporosis treatment: is it the same in Asian and Caucasian (benefit/risk including AFF) — P. Ebeling
12.30
INDUSTRY-SPONSORED LUNCH SYMPOSIUM (Detailed programme here)
13.30
BREAK AND POSTER VIEWING SESSION
14.00
MEET-THE-EXPERT SESSIONS
  • Recent Fracture: when and how to treat osteoporosis — J.-K. Lee
  • Chronic renal failure: how to assess and manage bone fragility? — P. Ebeling
  • Vitamin D: which & how much? — A. Mithal
  • Protein intake and supplement in fracture patient — R. Rizzoli
14.45
PLENARY SESSION III
Quality of life in musculoskeletal diseases - ESCEO symposium
Chair: R. Rizzoli & E. Biver
  • Introduction — O. Bruyère
  • Assessment of quality of life in osteoporosis — J.-M. Kaufman
  • Assessment of quality of life in osteoarthritis — C. Cooper
  • Assessment of quality of life in sarcopenia — F. Buckinx
  • Discussion & Conclusion
16.15
INDUSTRY-SUPPORTED SESSION: IOF - APOA JOINT SESSION (more information here)
Osteoporosis - Orthopedic Surgery in Asia Pacific, The Missing Link?
  • Introduction — S. Ferrari
  • Osteoporosis in Asia Pacific — P. Ebeling
  • Orthopedic Surgery in Asia Pacific — D. Choon
  • IOF-APOA Collaboration - “The Link” — J. K. Lee
  • Launch of the IOF-APOA collaboration and Promising Future — C. Cooper
17.00
ORAL COMMUNICATIONS SESSION II
Chair: M. Chandran
  • 17.00 — OC4 — ANTI-OSTEOPOROSIS MEDICATIONS ARE ASSOCIATED WITH DECREASED MORTALITY AFTER HIP FRACTURE — Y. Li
  • 17.10 — OC5 — ASIA-PACIFIC BONE ACADEMY FRACTURE LIAISON SERVICE EDUCATIONAL INITIATIVE — P. Ebeling
  • 17.20 — OC6 — INCREASED CORTICAL POROSITY AND REDUCED TRABECULAR DENSITY ARE NOT NECESSARILY SYNONYMOUS WITH BONE LOSS AND MICROSTRUCTURAL DETERIORATION — E. Seeman
17.30
19.00
CNS ROUNDTABLE
Mapping calcium intake
Chair: B. Dawson-Hughes & A. Mithal
  • Dietary calcium intake worldwide (Ca map) — B. Dawson-Hughes
  • Consequences of low calcium intake in the Asia Pacific region — R. Rizzoli
  • Calcium supplements and fracture prevention — A. Mithal
  • Calcium intake and its implication in China — W. Xia
  • Roundtable: Potential strategies to improve calcium intake - What is feasible within the low intake countries
Sat, December 1
08.00
17.00
EXHIBITION AREA OPEN
08.15
MEET-THE-EXPERT SESSIONS
  • Falls prevention: is it possible — W.-L. Hsu
  • Bone loss in early menopause: to treat or not? — A. Vincent
  • Genetic markers of bone fragility: what have we learned — E. Duncan
  • Can we trust bone turnover markers to improve fracture assessment — H. Morris
09.00
PLENARY SESSION IV
Assessment and management of bone fragility beyond idiopathic osteoporosis (IOF-ANZBMS session)
Chair: E. Biver & P. Croucher (ANZBMS)
  • Fracture prevention in cancer patients — E. Biver
  • Fracture prevention in diabetes patients — M. Chandran
  • When to suspect a genetic disorder? — J. Eisman
10.15
ORAL COMMUNICATIONS SESSION III
Chair: J. Center
  • 10.15 — OC7 — EFFECTS OF TERIPARATIDE ON HIP AND UPPER LIMB FRACTURES IN PATIENTS WITH OSTEOPOROSIS: A SYSTEMATIC REVIEW AND META-ANALYSIS — M. Hassanzai
  • 10.25 — OC8 — DIGITAL X-RADIOGRAMMETRY COMBINED WITH MAMMOGRAPHY TO SCREEN POSTMENOPAUSAL WOMEN FOR REDUCED BONE MINERAL DENSITY — A. Rao
  • 10.35 — OC9 — DO DEFINITIONS OF SARCOPENIA PREDICT FRACTURE RISK INDEPENDENT OF FRAX, FALLS AND BMD? (A META-ANALYSIS OF THE OSTEOPOROTIC FRACTURES IN MEN (MROS) STUDY) — H. Johansson
  • 10.45 — OC10 — ASSESSING CLINICAL UTILITY (IMPACT) OF GENETIC PROFILING IN FRACTURE RISK ASSESSMENT: A DECISION CURVE ANALYSIS APPROACH — T. Ho-Le
11.00
PLENARY SESSION V
New insights in the management of knee osteoarthritis - ESCEO Symposium
Chair: C. Cooper & F. Cicuttini
  • Welcome — C. Cooper
  • The 2014-2016 ESCEO algorithm for the management of knee osteoarthritis — O. Bruyère
  • New insights on the safety of anti-osteoarthritis medications — E. Dennison
  • New clinical evidence supporting the use of SYSADOAs as a first-line background treatment in knee osteoarthritis — J.-Y. Reginster, G. Honvo, A. Geerinck, O. Bruyère
  • Update of the 2014-2016 ESCEO algorithm for the managment of knee osteoarthritis — C. Cooper
  • Discussion & Conclusion — C. Cooper
12.30
INDUSTRY-SPONSORED SATELLITE SYMPOSIUM (Detailed programme here)
13.30
BREAK AND POSTER VIEWING SESSION
14.00
IOF-OA-ANZBMS JOINT SESSION
Chair: G. Lyubomirsky & B. Dawson-Hughes
  • Exercise and osteoporosis — B. Beck
  • Monetary cost of osteoporosis — J. A. Kanis
  • Morbidity and mortality of osteoporosis — J. Center
14.45
IOF-AGNOVOS HEALTHCARE YOUNG INVESTIGATOR AWARDS
Chair: A. Mithal
  • 14.51 — P118 — ORAL BISPHOSPHONATE USE AND ALL-CAUSE MORTALITY IN PATIENTS WITH ADVANCED (STAGE IIIB+) CHRONIC KIDNEY DISEASE: A POPULATION-BASED COHORT STUDY — D. Alarkawi
  • 15.00 — P050 — PREDICTION OF FRACTURES IN MEN WITH DYSGLYCAEMIA USING FRAX (AUS) — K. Holloway-Kew
  • 15.09 — P137 — ATYPICAL FEMUR FRACTURES IN AN AUSTRALIAN HOSPITAL SETTING: INCIDENCE, PATIENT RISK FACTORS AND DENSITOMETRIC CHARACTERISTICS — H. Nguyen
  • 15.18 — P046 — ASSOCIATIONS BETWEEN PAIN AT MULTIPLE SITES AND PREVALENT AND INCIDENT FRACTURES IN OLDER ADULTS — F. Pan
  • 15.27 — P011 — MID-CALF SKELETAL MUSCLE DENSITY AND ITS ASSOCIATIONS WITH ACCELEROMETER- DETERMINED PHYSICAL ACTIVITY, BONE HEALTH AND INCIDENT 12-MONTH FALLS IN OLDER ADULTS: THE HEALTHY AGEING INITIATIVE — D. Scott
  • 15.36 — P083 — PERSISTENT HIGH-IMPACT ACTIVITY AND FITNESS DURING ADOLESCENCE AND EARLY ADULTHOOD AND BONE DENSITY AND MICROARCHITECTURE IN EARLY ADULTHOOD — Y. Yang
14.45
MEET-THE-EXPERT SESSIONS
  • Osteosarcopenia — G. Duque
  • Glucocorticoid osteoporosis — E. Dennison
  • Assessment of physical strength and performance — F. Buckinx
15.45
17.00
PLENARY SESSION VI
Osteoporosis treatment: update
Chair: J. K. Lee & S. Ferrari
  • Benefit/Risk of long term treatment — S. Ferrari
  • Fracture risk off therapy — E. Dennison
  • Closing the gap in the treatment of patients at imminent risk of fracture: role of the new anabolic agents — E. Biver